Application of Three- Dimensional Visualization Combined With ICG Molecular Fluorescence Imaging in Hepatolithiasis

Launched by ZHUJIANG HOSPITAL · Jun 3, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new way to help patients with a condition called hepatolithiasis, which involves stones in the liver. Researchers want to see if using a combination of advanced 3D imaging and a special dye called ICG (indocyanine green) can improve the results of surgery compared to standard methods. The goal is to find out if these new techniques can help patients recover better after surgery.

To be eligible for this trial, participants need to be at least 18 years old and have been diagnosed with hepatolithiasis, meaning they have liver stones that require surgery. However, individuals with serious health issues or certain other conditions will not be able to participate. If you join the study, you will receive care that includes these advanced imaging techniques during your surgical treatment. The trial is not yet recruiting participants, so more information will be available soon for those interested.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged ≥18 years, of any gender; The diagnosis was hepatolithiasis；Surgical treatment has been performed.
• Exclusion Criteria:
• • Patients with severe cardiac, pulmonary, cerebral, renal dysfunction or other clinical contraindications who are unable to tolerate surgical treatment; Patients with malignant transformation; Lack of clinical data.